Document Detail

Thalidomide for treatment of refractory epilepsy.
MedLine Citation:
PMID:  21035311     Owner:  NLM     Status:  In-Process    
We have experimentally shown that thalidomide has strong anticonvulsant properties. In an open label study, eight male patients with refractory epilepsy received thalidomide at daily-doses of 200 mg during 1 year, frequency of seizures before and during treatment were compared. The mean number of seizures before thalidomide administration was 26 ± 4 per month; it decreased to 7 ± 1 along thalidomide therapy. Our results indicate that thalidomide has strong therapeutic effects in refractory epilepsy.
Guadalupe Palencia; Iris E Martinez-Juarez; Alejandra Calderon; Carol Artigas; Julio Sotelo
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-28
Journal Detail:
Title:  Epilepsy research     Volume:  92     ISSN:  1872-6844     ISO Abbreviation:  Epilepsy Res.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8703089     Medline TA:  Epilepsy Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  253-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier B.V. All rights reserved.
Neuroimmunology Unit, National Institute of Neurology and Neurosurgery of Mexico, Mexico.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Risk factors of neurosensory deficits in lower third molar surgery: an literature review of prospect...
Next Document:  The epidemiology of epilepsy in the Russian Federation.